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1. Introduction
   Trypanosoma evansi (T. evansi) is the etiologic agent of a 
disease known as Mal das cadeiras or surra in horses[1]. Surra is 
an important disease in a wide geographic region (Africa, Asia, 
and South and Central America), and infects mainly camels, 
cattle, horses, buffalos and some wild animals[2-4]. The parasite 
is transmitted by infected blood through haematophagous insects 
such as tabanid flies[5,6]. The disease is endemic in some regions 
(Mato Grosso, Pantanal in Brazil,) and in other regions it occurs in 
outbreaks, hindering the prophylaxis and control.
   The treatment of this disease in Brazil is based on diminazene 
aceturate (DA), but this drug is ineffective for umpteen animals[7,8]. 
Most of the drugs used for the treatment of the disease do not 
provide total elimination of the infection and are associated with 
recurrence and mortality[8]. In many cases, DA treatment may 
not be effective, leading to recurrent parasitemia[8-10], as well as 
hepatotoxicity, and nephrotoxicity[1,11]. As a result, researchers have 
tested natural products such as oils of copaiba, andiroba, aroeira, tea 
tree[12-14], and propolis extract[15].
   Aescin is the predominant active constituent of Aesculus 
hippocastanum seed extract, which is a mixture of triterpene, 
saponins, consisting of A, B, C and D aescin[16]. Research has 
been focused on plant secondary compounds, such as saponins, 
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concentrations (0.5%, 1.0% and 2.0%) and exposure times (0, 1, 3, 6 and 9 h). In vivo tests 
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the treatment of trypanosomosis when used in association with other trypanocidal drugs.
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for the control of parasite in sheep[17,18]. According to Carrasco 
and Vidrio aescin has been shown to be effective in the treatment of 
inflammatory conditions[19]. Actually, some studies have indicated 
that aescin is also a potential anticancer agent[20,21].
   The field of nanoparticle synthesis, assembly, and application 
in biology is a fast growing area of nanotechnology and 
nanomedicine[22]. Through the development of materials that 
exhibit novel optical, chemical, and electrical properties at 
the nanometer-sized scale, it is hoped that it will be possible 
improve therapies for disease[23]. In this context, it can be 
highlighted the liposomes. Liposomes are spherical self-closed 
structures, composed of curved lipid bilayers, that encapsulate 
both hydrophilic and lipophilic substances[24]. The simplicity of 
production, their biocompatibility, low toxicity, size and similar 
composition to cells make them a revolutionary tool in biomedical 
domain. Based on the needs for curative therapy of T. evansi and 
on the properties of aescin and the antiparasitic properties of 
saponins mentioned above, the present study analyzed for the first 
time the in vitro and in vivo activity of aescin and aescin liposomes 
against T. evansi.
 
2. Materials and methods
2.1. T. evansi isolate
   This study was set up in two consecutive experiments (in vitro and 
in vivo). The same T. evansi isolate was used in both experiments[10]. 
Two rats (R1 and R2) were infected intraperitoneally with 
trypomastigotes contaminated blood kept cryopreserved in liquid 
nitrogen. This procedure was performed to obtain a large amount of 
viable parasites for in vitro tests (R1), and to infect the experimental 
groups (R2).
2.2. Aescin and aescin liposomes
   Aescin was purchased from (Sigma-Aldrich®, St. Louis, USA). 
Aescin liposomes were prepared with 0.5% aescin using a 
proprietary method from Inventiva®. Particle size and polydispersion 
index were evaluated by dynamic light scattering. Zeta potential was 
evaluated using electrophoretic mobility technique. The samples 
were diluted in Milli-Q water (500×) and the assays were performed 
using Zeta Sizer Nanoseries, Malvern. The pH was assessed by 
direct use of Digimed potentiometer according to Da Silva[25].
2.3. In vitro tests
   The culture medium for T. evansi was adapted from Baltz as 
previously published by Baldissera[13,26]. The trypomastigotes 
were acquired from the infection of one rat (R1) with a T. evansi 
isolate. Five days post-infection rat showed high parasitemia (7.5伊
106 trypanosomes/µL). The rat was was anesthetized with isoflurane 
for blood collection by cardiac puncture, and blood was stored 
in ethylene diamine tetraacetic acid tubes. For trypanosomes 
separation, each 200 µL blood was diluted in complete culture 
medium (200 µL), stored in microcentrifuge tubes and centrifuged 
for 10 min at 1 550 r/min. The supernatant was removed and 
resuspended in culture medium and the number of parasites was 
counted in a Neubauer chamber.
   The culture medium with the parasites was distributed in microtiter 
plates (270 µL/well), followed by the addition of 25 µL of aescin 
(diluted in culture medium) at concentrations of 0.5%, 1.0% and 
2.0%. The aescin liposomes also were used at concentrations of 
0.5%, 1.0% and 2.0 %. A positive control (DA at a dilution of 0.5%) 
was also used, at the same volume (25 µL). The tests were performed 
in duplicates and the parasites were counted at 1, 3, 6 and 9 h after 
the onset of the experiment in Neubauer chambers. The microtiter 
plates were placed in a 5% CO2 incubator at 37 °C according to 
Baltz[26].
2.4. In vivo test
2.4.1. Animal model
   Forty-two, female, 60-day-old-mice weighing an average of 
(23.0±0.7) g were used as the experimental model. They were kept in 
cages with six females each, housed on a light/dark cycle of 12 h, in an 
experimental room with controlled temperature (23±1) ºC and humidity 
70%. They were fed with commercial feed, and water ad libitum. All 
animals were subjected to a period of 10 d for adaptation. 
2.4.2. Experimental design and parasitemia estimation 
   The mice were divided into seven groups (A to G). Group A 
consisted of uninfected mice and untreated (negative control); Group 
B consisted of infected mice and untreated (positive control); Group 
C was composed of animals infected and treated with aescin 60 mg/kg; 
Group D was composed of animals infected and treated with aescin 
100 mg/kg; Group E was composed of animals infected and treated 
with aescin liposomes 60 mg/kg; Group F was composed of animals 
infected and treated with aescin liposomes 100 mg/kg; Group G was 
composed of animals infected and treated with DA. Infected animals 
were inoculated intraperitoneally with 0.05 mL of blood from one 
rat containing 1.1伊106 trypanosomes.
   The DA was administered in a single dose of 7.0 mg/kg, 
intraperitoneally injection, and 1 h after infection of the animals. 
Aescin and aescin liposomes were administered orally for 4 d, 
starting the 1 h following infection.
   The evolution of parasitemia and the effect of the treatment were 
daily monitored through blood smear. Each slide was prepared with 
fresh blood collected from the tail vein, stained by the panoptic 
method, and visualized at a magnification of 1000伊 according to Da 
Silva[27].
2.4.3. Treatment efficacy
   Treatment efficacy was determined by the number of mice that 
did not show clinical signs of T. evansi infection after treatment. 
Prepatent period, longevity and animal mortality were also observed. 
2.5. Statistical analysis
   Data from in vitro were analyzed by analysis of variance for 
repeated measures and comparison of concentrations tested for 
aescin. Data of the prepatent period and longevity were submitted 
for analysis of variance according to Duncan test (P<0.05). 
3. Results
3.1. Aescin liposomes
   The prepared suspension was evaluated regarding to their physical-
chemical properties. The particle size was (223±6) nm and the 
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polydispersion index was (0.211±0.059) with a zeta potential of 
(-18.1±1.7) mV. 
3.2. In vitro test
   The results showed a trypanocidal effect of aescin and aescin 
liposomes on T. evansi directly proportional to the concentration 
used (Figure 1). After 1 h, there were no living trypomastigotes 
in  1.0% and 2.0% concentrat ions.  A reduct ion of  l ive 
trypomastigotes was observed at the concentration of 0.5% when 
compared with the control group. After 3 h of the assay, there 
were no living trypomastigotes in 0.5% concentration and DA 
treatments (Figure 1A).
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Figure 1. In vitro, trypanocidal activity in concentrations 0.5%, 1.0% 
and 2.0% of aescin (A) and aescin liposomes (B) against T. evansi when 
compared to the control (not-treated) and diminazene aceturate (anti-
protozoa drug). 
The results within a circle are not statistically different (P>0.05), at the 
same time (h).
   The aescin liposomes results are shown in Figure 1B. After 1 h, a 
reduction of live trypomastigotes was observed at the concentrations 
of 0.5%, 1.0% and 2.0%, respectively, when compared with 
the control group. After 3 h of the assay, there were no living 
trypomastigotes in 2.0% and 1.0% concentration and DA, and a 
reduction of live trypomastigotes at the concentration of 0.5%. After 
6 h of the assay, there were no living trypomastigotes forms in 0.5% 
concentration. To the contrary, in control tests (not using drugs), the 
parasites were all alive (Figure 1), which validates our experiment.
3.3. In vivo test
   There were no differences between groups regarding the prepatent 
period (Table 1). Longevity of the group A was exactly represented 
by the days that the experiment lasted (10 d). Longevity in the 
groups B, C, D, E, F and G were 4.0, 5.1, 11.5, 6.0, 10.5 and 40 
days, respectively. The groups C, D, E and F had no curative efficacy, 
but the groups D, E and F increased longevity compared to the group 
B. The animals treated with DA showed negative blood smear during 
the 40 days of the period of our study.
Table 1
In vivo test-mean and standard deviation of the prepatent period, longevity 
and mortality using treatment with aescin, aescin liposomes and DA in mice 
experimentally infected by T. evansi. 
Groups 
(n=6)
Treatment# Prepatent 
period (d)
Longevity (d) Mortality 
(n)
A Negative control - 40.00±0.00a 0/6
B Positive control 1.16±0.40a 4.00±0.63d 6/6
C Aescin (60 mg/kg) 1.83±0.75a 5.10±0.98cd 6/6
D Aescin (100 mg/kg) 2.00±0.89a 11.50±1.01b 6/6
E Aescin liposomes (60 mg/kg) 2.11±0.75a 6.00±1.22c 6/6
F Aescin liposomes (100 mg/kg) 1.66±1.03a 10.50±1.04b 6/6
G DA (7.0 mg/kg) 0.00±0.00a 40.00±0.00a 0/6
Means followed by same letter in the same column do not differ significantly 
in the Duncan test; The experiment lasted 40 d post-infection; #: Survival 
animals in the end of experiment, showed negative PCR and blood smears.
4. Discussion
   This study observed a trypanocidal action in vitro and in vivo of 
aescin and aescin liposomes. The results showed a dose-dependent 
trypanocidal effect of aescin and aescin liposomes against T. evansi 
trypomastigotes in vitro. The aescin had apparently a faster trypanocidal 
effect in vitro than the aescin liposome. This was expected, since 
nanotechnology process usually provides a more slow and gradual 
properties of release. Saponins have been cited by researchers because 
of their active substances with various therapeutic properties and 
have a range of biological and pharmacological properties such as 
antimicrobial, anti–inflammatory and anti-cancer[28]. In vivo and in 
vitro, studies have shown the effect of saponins against protozoa in the 
rumen of lambs[29,30]. There are also as reports the saponins extracts 
from Maesa balansae, Careya arborea and Astragalus oleifolius having 
antileishmaninal activity[31].
   Based on these previous promising in vitro results, we have 
designed an in vivo experiment using mice infected by T. evansi as 
a model. However, the therapeutic protocol used with aescin had no 
curative effect for all the groups, but in a group’s treated with aescin 
and aescin liposomes (Groups D, E and F), an increase in longevity 
of animals was observed. According to Kedzierski[32], β-aescin, 
the major compound found in Aesculus hippocastanum, showed 
moderate active on the intracellular amastigote stage of Leishmania 
infantum and highest active on the extracellular promastigote stage. 
The accurate mechanism the active of β-aescin is uncertain, but 
saponins show anti-leishmaninal activity through the induction of 
apoptosis or programmed cell death in the parasite[33,34].
   Biological compounds with trypanocidal activity incorporated 
into liposomes are described since 1987. Liposomes containing 
stearylamine rapidly killed epimastigotes, amastigotes and 
trypomastigotes forms of Trypanosome cruzi in vitro[35]. Van de 
Ven also demonstrate in vitro that β-aescin nanoparticles showed 
leishmanial activity[36]. This study also looked for action against of 
T. evansi, a protozoon of the same family of Trypanosome cruzi and 
Leishmania sp. The best therapeutic response observed with use of 
liposomes is mainly the ability to modify the surface of target cells 
and tissues, and the absorption peak or phagocytic mechanisms and 
the ability to overcome intracellular barriers and to massively deliver 
trypanocidal drugs into an extremely small volume[37]. 
   The utilization of liposomes is advantageous because these 
nanoparticles are very similar to the cell membranes interacting 
more closely and with greater efficiency with cells and tissues[38]. 
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In addition, liposomes are nontoxic, biodegradable and can be 
produced easily and quickly on a large scale. Finally, they can be 
administered by intravenous, ocular, pulmonary, or dermal route[24]. 
It is also important to emphasize the great advantage of overcoming 
physicochemical properties of encapsulated drugs (such as water 
solubility or membrane), thus improving the pharmacodynamics 
(therapeutic effect potentiation), pharmacokinetics (absorption 
control and tissue distribution) and their toxicological effects 
(reduction of local and systemic toxicity)[39]. Barratt also showed 
that some liposomes may lead to dose reduction, decreasing the 
frequency used without loss of effectiveness, reducing costs of 
therapy and the risk of toxicity, thus demonstrating that the strategy 
to modify the biodistribution profile of the drug is more effective 
than the free drug use[40].
   Based on the result it was concluded that pure aescin pure and 
liposome aescin has trypanocidal action against T. evansi in culture 
medium, to cause induction to apoptosis or programmed cell death 
in the parasite. Nevertheless, the treatment had no curative efficacy 
in infected mice with T. evansi, however, it demonstrated increased 
longevity of animals. 
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Comments 
Background
   Surra, a disease caused by T. evansi, is of economic importance 
and affects a wide range of domestic animals such as horses, cattles, 
camels, buffalos as well as wild animals. The currently available 
drugs are usually expensive and toxic, and their effectiveness in 
most cases has been curtailed by the development of drug resistance. 
Thus, the present research evaluated the trypanocidal action of 
aescin and aescin liposomes against T. evansi as potential treatments 
for trypanosomosis.
  
Research frontiers
   Development of new trypanocidal drugs is based on rational 
drug design, synthesis or natural product screening, but also taking 
advantage of compounds already in use against other animal or 
human pathogens for the development of new drugs. The current 
state of knowledge of parasite biochemistry and the sequencing 
of the parasite genome has favoured the development of new 
chemotherapeutic approaches based on newly validated biochemical 
targets and the present research is within these bounds. 
Related reports
   Aescin is a mixture of saponins that has been shown to have 
anti-inflammatory, vasoconstrictor and vasoprotective properties. 
Research has demonstrated the bioactivity and therapeutic effects of 
saponins such as aescin. Saponins can complex with cholesterol to 
form pores in the cell membrane bilayers. Their modes of action can 
augment the cytotoxicity of toxins against cells. 
Innovations and breakthroughs
   In the present study, the authors have demonstrated the trypanocidal 
effects of aescin and aescin liposomes on T. evansi, a disease of 
economic importance.
  
Applications
   The saponins present in aescin can potentiate the treatment of 
trypanosomosis when used with other trypanocidl drugs. This may also 
alleviate the potential for drug resistance.  
Peer review
   The present study has addressed an important aspect of 
trypanosomosis research by evaluating the effectiveness of a potential 
adjuvant to trypanosomosis treatment in animals, aescin and aescin 
liposomes. Undoubtedly, the rearch results will add value to the current 
knowledge in this field. 
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